LIVIVO - Suchergebnisse -

Suchergebnis

Treffer 1 - 10 von insgesamt 20

Suchoptionen

Artikel: Prospective Observational Study of COVID-19 Vaccination in Patients with Thoracic Malignancies: Adverse Events, Breakthrough Infections and Survival Outcomes.

Janzic, Urska / Janzic, Andrej / Agbarya, Abed / Bidovec-Stojkovic, Urska / Mohorcic, Katja / Caks, Marina / Korosec, Peter / Rijavec, Matija / Skof, Erik

Biomedicines

2024 Band 12, Heft 3

Abstract: Due to the devastating COVID-19 pandemic, a preventive tool in the form of vaccination was introduced. Thoracic cancer patients had one of the highest rates of morbidity and mortality due to COVID-19 disease, but the lack of data about the safety and ... ...

Abstract	Due to the devastating COVID-19 pandemic, a preventive tool in the form of vaccination was introduced. Thoracic cancer patients had one of the highest rates of morbidity and mortality due to COVID-19 disease, but the lack of data about the safety and effectiveness of vaccines in this population triggered studies like ours to explore these parameters in a cancer population. Out of 98 patients with thoracic malignancies vaccinated per protocol, 60-75% experienced some adverse events (AE) after their first or second vaccination, most of them were mild and did not interfere with their daily activities. Out of 17 severe AEs reported, all but one were resolved shortly after vaccination. No significant differences were noted considering AE occurrence between different cancer therapies received after the first or second vaccination dose,
Sprache	Englisch
Erscheinungsdatum	2024-02-27
Erscheinungsland	Switzerland
Dokumenttyp	Journal Article
ZDB-ID	2720867-9
ISSN	2227-9059
ISSN	2227-9059
DOI	10.3390/biomedicines12030535
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Various clinical presentations of uveitis associated with durvalumab treatment

Vrabic Nika / Fakin Ana / Mekjavic Polona Jaki / Janzic Urska / Vrankar Martina / Valentincic Natasa Vidovic

Radiology and Oncology, Vol 56, Iss 2, Pp 129-

2022 Band 137

Abstract: Immune checkpoint inhibitors (ICI) are becoming increasingly common in treating several cancer types. Durvalumab is a human IgG1 monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80 and has recently been approved for the treatment of extensive- ... ...

Abstract	Immune checkpoint inhibitors (ICI) are becoming increasingly common in treating several cancer types. Durvalumab is a human IgG1 monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80 and has recently been approved for the treatment of extensive-stage small-cell lung cancer (ES-SCLC) and locally advanced unresectable (NSCLC). The present review aimed to analyse immune-mediated uveitis, secondary to durvalumab treatment, through a review of the literature and a presentation of two clinical cases.
Schlagwörter	durvalumab ; uveitis ; optic disc oedema ; immune checkpoint inhibitor ; adverse effects ; Medical physics. Medical radiology. Nuclear medicine ; R895-920
Sprache	Englisch
Erscheinungsdatum	2022-04-01T00:00:00Z
Verlag	Sciendo
Dokumenttyp	Artikel ; Online
Datenquelle	BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

Volltext online

Volltext online

Zusatzmaterialien

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Artikel ; Online: Various clinical presentations of uveitis associated with durvalumab treatment.

Vrabic, Nika / Fakin, Ana / Mekjavic, Polona Jaki / Janzic, Urska / Vrankar, Martina / Valentincic, Natasa Vidovic

Radiology and oncology

2022 Band 56, Heft 2, Seite(n) 129–137

Abstract: Background: Immune checkpoint inhibitors (ICI) are becoming increasingly common in treating several cancer types. Durvalumab is a human IgG1 monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80 and has recently been approved for the treatment ... ...

Abstract	Background: Immune checkpoint inhibitors (ICI) are becoming increasingly common in treating several cancer types. Durvalumab is a human IgG1 monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80 and has recently been approved for the treatment of extensive-stage small-cell lung cancer (ES-SCLC) and locally advanced unresectable (NSCLC). The present review aimed to analyse immune-mediated uveitis, secondary to durvalumab treatment, through a review of the literature and a presentation of two clinical cases. Patients and methods: A literature review using PubMed search was conducted to identify cases of uveitis secondary to durvalumab and cases of uveitis with optic disc oedema secondary to ICI use that were reported prior to November 14, 2021. Additionally, we report two cases of uveitis consequent on durvalumab treatment. Results: Five cases of uveitis secondary to durvalumab use were identified in the literature. Anterior, posterior uveitis and vasculitis were reported. Additionally, we present a case of bilateral intermediate uveitis with bilateral optic disc oedema and a case of bilateral posterior uveitis. Our further search revealed 12 cases of uveitis with optic disc oedema secondary to ICI use, with the majority of cases reported secondary to PD-1 inhibitors. Conclusions: Rarely reported, uveitis secondary to durvalumab can present various clinical pictures and requires a thorough diagnostic workup. Once the diagnosis is established, treatment, commonly with a local or systemic corticosteroid, should be adapted to the severity of the inflammation.
Mesh-Begriff(e)	Antibodies, Monoclonal/adverse effects ; Humans ; Immune Checkpoint Inhibitors ; Lung Neoplasms/drug therapy ; Papilledema/drug therapy ; Uveitis/drug therapy ; Uveitis, Posterior/drug therapy
Chemische Substanzen	Antibodies, Monoclonal ; Immune Checkpoint Inhibitors ; durvalumab (28X28X9OKV)
Sprache	Englisch
Erscheinungsdatum	2022-04-12
Erscheinungsland	Poland
Dokumenttyp	Case Reports ; Journal Article ; Review
ZDB-ID	1128829-2
ISSN	1581-3207 ; 0485-893X ; 1318-2099
ISSN (online)	1581-3207
ISSN	0485-893X ; 1318-2099
DOI	10.2478/raon-2022-0007
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.B 2674: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel ; Online: Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations.

Janzic, Urska / Shalata, Walid / Szymczak, Katarzyna / Dziadziuszko, Rafał / Jakopovic, Marko / Mountzios, Giannis / Płużański, Adam / Araujo, Antonio / Charpidou, Andriani / Agbarya, Abed

International journal of molecular sciences

2023 Band 24, Heft 16

Abstract: BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in these cases for the first and second line is not clear. An international registry was created for patients with advanced NSCLC harboring BRAF or cMET exon 14 skipping ... ...

Abstract	BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in these cases for the first and second line is not clear. An international registry was created for patients with advanced NSCLC harboring BRAF or cMET exon 14 skipping mutations, diagnosed from January 2017 to June 2022. Clinicopathological and molecular data and treatment patterns were recorded. Data on 58 patients, from eight centers across five countries, were included in the final analysis. We found that 40 patients had the cMET exon 14 skipping mutation and 18 had the BRAF V600E mutation. In total, 53 and 28 patients received first- and second-line treatments, respectively, among which 52.8% received targeted therapy (TT) in the first line and 53.5% in the second line. The overall response rate (ORR) and disease control rate (DCR) for first-line treatment with TT vs. other treatment such as immune checkpoint inhibitors ± chemotherapy (IO ± CT) were 55.6% vs. 21.7% (
Mesh-Begriff(e)	Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Proto-Oncogene Proteins B-raf/genetics ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Exons/genetics ; Mutation
Chemische Substanzen	Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; BRAF protein, human (EC 2.7.11.1)
Sprache	Englisch
Erscheinungsdatum	2023-08-16
Erscheinungsland	Switzerland
Dokumenttyp	Journal Article
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms241612840
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel: A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers.

Janzic, Urska / Bidovec-Stojkovic, Urska / Korosec, Peter / Mohorcic, Katja / Mrak, Loredana / Caks, Marina / Ravnik, Maja / Skof, Erik / Rijavec, Matija

Vaccines

2023 Band 11, Heft 6

Abstract: Background: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to assess the immunogenicity, efficacy, and safety of ... ...

Abstract	Background: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to assess the immunogenicity, efficacy, and safety of COVID-19 vaccination in this cohort. Methods: Patients with solid malignancies on active treatment were followed up after the primary course and booster third dose of vaccination to assess their anti-SARS-CoV-2 S1 IgG levels, efficacy in the case of SARS-CoV-2 infection, and safety. Results: Out of 125 patients receiving the primary course of vaccination, 66 patients received a booster third dose of mRNA vaccine, with a 20-fold increase in median anti-SARS-CoV-2 S1 IgG levels compared to Ab levels six months post-primary course of vaccination ( Conclusion: The third booster vaccination dose against COVID-19 in solid cancer patients triggers substantial immunogenicity and is safe and effective for preventing a severe COVID-19 disease course.
Sprache	Englisch
Erscheinungsdatum	2023-05-23
Erscheinungsland	Switzerland
Dokumenttyp	Journal Article
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines11061017
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study

Turnsek Nina / Devjak Rok / Edelbaher Natalija / Osrajnik Ilonka / Unk Mojca / Vidovic Dusanka / Jeric Tina / Janzic Urska

Radiology and Oncology, Vol 56, Iss 3, Pp 371-

2022 Band 379

Abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC). However, routine clinical practice is different between countries/institutions. ...

Abstract	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC). However, routine clinical practice is different between countries/institutions.
Schlagwörter	real-world study ; non-small cell lung cancer ; epidermal growth factor receptor ; t790m testing ; attrition ; Medical physics. Medical radiology. Nuclear medicine ; R895-920
Sprache	Englisch
Erscheinungsdatum	2022-08-01T00:00:00Z
Verlag	Sciendo
Dokumenttyp	Artikel ; Online
Datenquelle	BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

Volltext online

Volltext online

Zusatzmaterialien

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Artikel ; Online: Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia.

Janzic, Urska / Knez, Lea / Janzic, Andrej / Cufer, Tanja

Expert review of pharmacoeconomics & outcomes research

2019 Band 19, Heft 6, Seite(n) 717–723

Abstract: ... ...

Abstract	Objectives
Mesh-Begriff(e)	Antineoplastic Agents/economics ; Antineoplastic Agents/supply & distribution ; Health Services Accessibility/economics ; Health Services Accessibility/statistics & numerical data ; Humans ; Neoplasms/drug therapy ; Reimbursement Mechanisms/economics ; Slovenia ; Societies, Medical ; Time Factors
Chemische Substanzen	Antineoplastic Agents
Sprache	Englisch
Erscheinungsdatum	2019-12-11
Erscheinungsland	England
Dokumenttyp	Journal Article
ZDB-ID	2208481-2
ISSN	1744-8379 ; 1473-7167
ISSN (online)	1744-8379
ISSN	1473-7167
DOI	10.1080/14737167.2019.1702879
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 6194: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer

Ljubicic Lidija / Janzic Urska / Unk Mojca / Terglav Ana Sophie / Mohorcic Katja / Seiwerth Fran / Bitar Lela / Badovinac Sonja / Plestina Sanja / Korsic Marta / Kukulj Suzana / Samarzija Miroslav / Jakopovic Marko

Radiology and Oncology, Vol 57, Iss 3, Pp 397-

a multicenter retrospective real-world analysis

2023 Band 404

Abstract: The standard first-line systemic treatment for patients with non-oncogene addicted advanced nonsquamous non-small cell lung cancer (NSCLC) is immunotherapy with immune checkpoint inhibitors (ICI) and/or chemotherapy (ChT). Therapy after failing ICI +/− ... ...

Abstract	The standard first-line systemic treatment for patients with non-oncogene addicted advanced nonsquamous non-small cell lung cancer (NSCLC) is immunotherapy with immune checkpoint inhibitors (ICI) and/or chemotherapy (ChT). Therapy after failing ICI +/− ChT remains an open question, and docetaxel plus nintedanib represent a valid second line option.
Schlagwörter	advanced nsclc ; antiangiogenic therapy ; docetaxel ; nintedanib ; real-world data ; Medical physics. Medical radiology. Nuclear medicine ; R895-920
Sprache	Englisch
Erscheinungsdatum	2023-09-01T00:00:00Z
Verlag	Sciendo
Dokumenttyp	Artikel ; Online
Datenquelle	BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

Volltext online

Volltext online

Zusatzmaterialien

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Artikel ; Online: Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT).

Janžič, Urška / Turnšek, Nina / Dediu, Mircea / Donev, Ivan Shterev / Lupu, Roxana / Teodorescu, Gabriela / Ciuleanu, Tudor E / Pluzanski, Adam

Current oncology (Toronto, Ont.)

2022 Band 29, Heft 8, Seite(n) 5833–5845

Abstract: The targeted therapy with tyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor mutation (EGFRm) in advanced non-small cell lung cancer (NSCLC) changed the treatment paradigm. REFLECT study (NCT04031898) ... ...

Abstract	The targeted therapy with tyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor mutation (EGFRm) in advanced non-small cell lung cancer (NSCLC) changed the treatment paradigm. REFLECT study (NCT04031898) explored
Mesh-Begriff(e)	Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; ErbB Receptors/genetics ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Mutation ; Protein Kinase Inhibitors ; Retrospective Studies
Chemische Substanzen	Protein Kinase Inhibitors ; EGFR protein, human (EC 2.7.10.1) ; ErbB Receptors (EC 2.7.10.1)
Sprache	Englisch
Erscheinungsdatum	2022-08-17
Erscheinungsland	Switzerland
Dokumenttyp	Clinical Study ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1236972-x
ISSN	1718-7729 ; 1198-0052
ISSN (online)	1718-7729
ISSN	1198-0052
DOI	10.3390/curroncol29080460
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 4305: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel ; Online: Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study.

Turnsek, Nina / Devjak, Rok / Edelbaher, Natalija / Osrajnik, Ilonka / Unk, Mojca / Vidovic, Dusanka / Jeric, Tina / Janzic, Urska

Radiology and oncology

2022 Band 56, Heft 3, Seite(n) 371–379

Abstract: Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC). However, routine clinical practice is different between countries/ ... ...

Abstract	Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC). However, routine clinical practice is different between countries/institutions. Patients and methods: The REFLECT study (NCT04031898) is a retrospective medical chart review that explored real-life treatment and outcomes of EGFRm NSCLC patients receiving first-line (1L) first-/second-generation (1G/2G) EGFR TKIs in 8 countries. This study included adult patients with documented advanced/metastatic EGFRm NSCLC with 1L 1G/2G EGFR TKIs initiated between Jan 2015 - Jun 2018. We reviewed data on clinical characteristics, treatments, EGFR/T790M testing patterns, and survival outcomes. Here, we report data from 120 medical charts in 3 study sites from Slovenia. Results: The Slovenian cohort (median age 70 years, 74% females) received 37% erlotinib, 32% afatinib, 31% gefitinib. At the time of data collection, 94 (78%) discontinuations of 1L TKI, and 89 (74%) progression events on 1L treatment were reported. Among patients progressing on 1L, 73 (82%) were tested for T790M mutation yielding 50 (68%) positive results, and 62 (85%) received 2L treatment. 82% of patients received osimertinib. Attrition rate between 1L and 2L was 10%. The median (95% CI) real-world progression free survival on 1L EGFR TKIs was 15.6 (12.6, 19.2) months; median overall survival (95% CI) was 28.9 (25.0, 34.3) months. Conclusions: This real-world study provides valuable information about 1G/2G EGFR TKIs treatment outcomes and attrition rates in Slovenian EGFRm NSCLC patients. The reduced attrition rate and improved survival outcomes emphasize the importance of 1L treatment decision.
Mesh-Begriff(e)	Adult ; Aged ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; ErbB Receptors/genetics ; Female ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Male ; Mutation ; Protein Kinase Inhibitors/therapeutic use ; Retrospective Studies
Chemische Substanzen	Protein Kinase Inhibitors ; ErbB Receptors (EC 2.7.10.1)
Sprache	Englisch
Erscheinungsdatum	2022-08-14
Erscheinungsland	Poland
Dokumenttyp	Clinical Study ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1128829-2
ISSN	1581-3207 ; 0485-893X ; 1318-2099
ISSN (online)	1581-3207
ISSN	0485-893X ; 1318-2099
DOI	10.2478/raon-2022-0025
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.B 2674: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Zum Seitenanfang

Ihre letzten Suchen

Zusatzmaterialien

Kategorien

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Fernleihe an ZB MED

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Fernleihe an ZB MED

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Fernleihe an ZB MED

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen